136 related articles for article (PubMed ID: 37725256)
1. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract][Full Text] [Related]
3. Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Lin D; Nguyen H; Shah R; Qiao Y; Hartman J; Sugarman R
Gastric Cancer; 2023 May; 26(3):415-424. PubMed ID: 36943511
[TBL] [Abstract][Full Text] [Related]
4. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
Kashiwa M; Matsushita R
Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
Mo X; Moriwaki K; Morimoto K; Shimozuma K
Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab plus chemotherapy
Cao X; Zhang M; Li N; Zheng B; Liu M; Song X; Cai H
Ther Adv Med Oncol; 2023; 15():17588359231171038. PubMed ID: 37223263
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
Kashiwa M
Eur J Health Econ; 2024 Apr; 25(3):459-470. PubMed ID: 37261572
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
13. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
14. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
Shu Y; Ding Y; Zhang Q
Front Oncol; 2022; 12():851522. PubMed ID: 35515123
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
18. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Lei M; Siemers NO; Pandya D; Chang H; Sanchez T; Harbison C; Szabo PM; Janjigian Y; Ott PA; Sharma P; Bendell J; Evans TRJ; de Braud F; Chau I; Boyd Z
Clin Cancer Res; 2021 Jul; 27(14):3926-3935. PubMed ID: 33782030
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
